Keep up-to-date with the LATEST news and publications on
routine HIV testing in the United States
since the 2008
National Summit on HIV Diagnosis, Prevention, and Access to Care.
FEB-03-12 The Forum publication “ Novel Clinical Trial Designs for the Development of New Antiretroviral Agents” is available electronically ahead of print in the journal AIDS. To view the full article, click here.
FEB-02-12 Please consider lending your name to a position statement to congress condemning the December 2011 reinstatement of the U.S. Congressional ban on the use of federal funds to support needle and syringe programs (NSPs). Scientists are especially encouraged to sign. Click here to learn more and to sign the petition.
FEB-02-12 The 2012 HIV Diagnostics Conference will provide an opportunity for participants to share their experiences with 4th generation antigen/antibody assays and data generated with this new HIV-1/2 diagnostic testing algorithm. The 2012 conference will be held December 12-14 at the Sheraton Atlanta Hotel in Atlanta, GA. Click here to read more.
JAN-23-12 Director of Research Advocacy at Project Inform joins the Forum's Executive Committee. To learn more about David Evans, click here.
Current Projects
Home
HCV Drug ResisSS 2012 v.1
JAN-30-12UPDATED: Recognizing the need for education
regarding HCV drug resistance, the Forum for Collaborative HIV Research's HCV
Drug Development Advisory Group (academicians, clinicians, researchers and
patient advocates) have contributed to a slide deck explaining resistance in
HCV, its consequences as well as its mitigation.
HCV Trials in the Post-Approval Era of Telaprevir and Boceprevir - The Way Forward
OCT-18-11
The October 18, 2011 meeting sponsored by the Forum was designed to
facilitate consensus on issues with the choice of control arm in HCV trials and
was
attended by representatives
from regulatory agencies (US, EMA, Health Canada), NIH, academia, pharmaceutical companies, and patient advocates.
HCV DrAG Meeting #7: Issues in HCV Clinical Trials
NOV-03-11 On November 3rd, the Forum held the 7th HCV DrAG Meeting in San Francisco, in conjunction with the 62nd American Association for the Study of Liver Diseases (AASLD) meeting "Issues in HCV Clinical Trials" focused on HCV viral load assays (LOD/LLOQ), as well as trials in current drug users and patients on opiate substitution therapy. With 72 people in attendance representing regulatory agencies, industry, academia, treatment, and advocacy, the panels had lively and productive discussions. In addition to spurring interest in special populations such as bleeding disorder and opiate substitution patients, the seventh HCV DrAG Meeting appears to have brought consensus on the HCV viral load cut-off and reporting, both of which will be used in trials and will translate into practice.
HCV Drug Access for People with Bleeding Disorders
OCT-17-11 The October 17, 2011 meeting entitled "HCV Drug Access
for People with Bleeding Disorders" was the first in a series of
meetings that will try and address
issues associated with providing access to, if indicated, combination
interferon-free experimental direct acting antivirals (DAAs).
The meeting was sponsored by the Forum, and was attended by representatives from regulatory agencies,
academia, hemophilia treatment centers, non-profits associated with database
management for those affected with bleeding
and blood clotting disorders, community medical practitioners, patient advocates and pharmaceutical
companies.
2011 HIV/AIDS Mini-Summit and C. Everett Koop HIV/AIDS Public Health Leadership Award
SEP-22-11 The Forum for Collaborative HIV Research hosted a special ceremony on
September 22, 2011 in Washington to honor Dr. Anthony Fauci, recipient of the 2011 C. Everett Koop HIV/AIDS Public Health Leadership Award. This ceremony was held in conjunction with a Mini-HIV/AIDS
Summit on Capitol Hill. Marking the 30th Anniversary of the beginning of
the HIV/AIDS crisis, this half-day symposium brought together many
of the nation’s scientists, clinicians, public health leaders and
advocates to (1) highlight progress in the ‘world’ of science and (2)
focus on the challenges of bringing that progress to fruition in the
‘world’ of clinical practice.
